193 related articles for article (PubMed ID: 34436637)
1. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
2. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
[TBL] [Abstract][Full Text] [Related]
3. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
4. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
5. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
[TBL] [Abstract][Full Text] [Related]
6. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
7. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Sorce G; Flammia RS; Hoeh B; Chierigo F; Hohenhorst L; Panunzio A; Stabile A; Gandaglia G; Tian Z; Tilki D; Terrone C; Gallucci M; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Prostate; 2022 Jun; 82(10):1040-1050. PubMed ID: 35365851
[TBL] [Abstract][Full Text] [Related]
8. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
9. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
[TBL] [Abstract][Full Text] [Related]
12. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
13. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
14. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
15. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
J Urol; 2021 Jul; 206(1):69-79. PubMed ID: 33683934
[TBL] [Abstract][Full Text] [Related]
16. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
[TBL] [Abstract][Full Text] [Related]
17. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
18. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy.
Hougen HY; Iakymenko OA; Punnen S; Ritch CR; Nahar B; Parekh DJ; Kryvenko ON; Gonzalgo ML
World J Urol; 2022 Aug; 40(8):2017-2023. PubMed ID: 35689106
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
